ZOMETA
LOE ApproachingNDAIV (INFUSION)INJECTABLEPriority Review
Approved
Feb 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
11
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZOMETA (zoledronic acid) is an intravenous bisphosphonate approved in 2002 for treating bone metastases and hypercalcemia of malignancy. The drug works by inhibiting osteoclast-mediated bone resorption, reducing skeletal complications in cancer patients. It is a small-molecule therapeutic delivered via IV infusion.
LOE Approaching
Product is in late-stage lifecycle with LOE approaching; expect declining team investment and transition planning toward pipeline alternatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (11)
Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer
Started Nov 2009
3 enrolled
Malignant Pleural EffusionNon Small Cell Lung Cancer
Comparison of Zometa Retention and Effect in Multiple Myeloma and Breast Cancer
Started Dec 2008
60 enrolled
Multiple MyelomaBreast Cancer
Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis
Started Sep 2008
156 enrolled
Non Small Cell Lung CancerBone MetastasesHigh NTX Level
Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis
Started Nov 2006
60 enrolled
Metastatic Breast CancerBone Metastases
To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer
Started Sep 2005
60 enrolled
Nasopharyngeal Cancer
Worked on ZOMETA at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.